Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.65 |
| ▸ | PDE4A | P27815 | 3/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495681 | 0.92 | F10 (0.61) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5794960 | 0.92 | F10 (0.63) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6493761 | 0.90 | F10 (0.59) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6494846 | 0.89 | F10 (0.60) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7070736 | 0.89 | F10 (0.71) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7070732 | 0.89 | F10 (0.65) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6494103 | 0.88 | F10 (0.58) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6502147 | 0.88 | F10 (0.58) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6502414 | 0.87 | F10 (0.60) | F10F2 | |
| SCHEMBL6496301 | 0.87 | F10 (0.60) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | F11, F10, F9 | F10 2/4885PDE4A 1745/4885PDE4B 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.